Phase II study of intravenous DX-8951f in patients with advanced ovarian, tubal, or peritoneal cancer refractory to platinum, taxane, and topotecan

C. F. Verschraegen; C. Levenback; M. Vincent; J. Wolf; M. Bevers; E. Loyer; A. P. Kudelka; J. J. Kavanagh; Texas

doi:10.1111/j.1749-6632.2000.tb07062.x

Phase II study of intravenous DX-8951f in patients with advanced ovarian, tubal, or peritoneal cancer refractory to platinum, taxane, and topotecan

C. F. Verschraegen, C. Levenback, M. Vincent, J. Wolf, M. Bevers, E. Loyer, A. P. Kudelka, J. J. Kavanagh, Texas

Gynecological Oncology & Reproductive Medicine

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Original language	English (US)
Pages (from-to)	349-351
Number of pages	3
Journal	Annals of the New York Academy of Sciences
Volume	922
DOIs	https://doi.org/10.1111/j.1749-6632.2000.tb07062.x
State	Published - 2000

ASJC Scopus subject areas

General Neuroscience
General Biochemistry, Genetics and Molecular Biology
History and Philosophy of Science

Access to Document

10.1111/j.1749-6632.2000.tb07062.x

Cite this

Verschraegen, C. F., Levenback, C., Vincent, M., Wolf, J., Bevers, M., Loyer, E., Kudelka, A. P., Kavanagh, J. J., & Texas (2000). Phase II study of intravenous DX-8951f in patients with advanced ovarian, tubal, or peritoneal cancer refractory to platinum, taxane, and topotecan. Annals of the New York Academy of Sciences, 922, 349-351. https://doi.org/10.1111/j.1749-6632.2000.tb07062.x

Verschraegen, CF, Levenback, C, Vincent, M, Wolf, J, Bevers, M , Loyer, E, Kudelka, AP, Kavanagh, JJ & Texas 2000, 'Phase II study of intravenous DX-8951f in patients with advanced ovarian, tubal, or peritoneal cancer refractory to platinum, taxane, and topotecan', Annals of the New York Academy of Sciences, vol. 922, pp. 349-351. https://doi.org/10.1111/j.1749-6632.2000.tb07062.x

@article{085df03ca6ba490a8fc092d5d2735872,

title = "Phase II study of intravenous DX-8951f in patients with advanced ovarian, tubal, or peritoneal cancer refractory to platinum, taxane, and topotecan",

author = "Verschraegen, {C. F.} and C. Levenback and M. Vincent and J. Wolf and M. Bevers and E. Loyer and Kudelka, {A. P.} and Kavanagh, {J. J.} and Texas",

year = "2000",

doi = "10.1111/j.1749-6632.2000.tb07062.x",

language = "English (US)",

volume = "922",

pages = "349--351",

journal = "Annals of the New York Academy of Sciences",

issn = "0077-8923",

publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Phase II study of intravenous DX-8951f in patients with advanced ovarian, tubal, or peritoneal cancer refractory to platinum, taxane, and topotecan

AU - Verschraegen, C. F.

AU - Levenback, C.

AU - Vincent, M.

AU - Wolf, J.

AU - Bevers, M.

AU - Loyer, E.

AU - Kudelka, A. P.

AU - Kavanagh, J. J.

AU - Texas,

PY - 2000

Y1 - 2000

UR - http://www.scopus.com/inward/record.url?scp=0034509617&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034509617&partnerID=8YFLogxK

U2 - 10.1111/j.1749-6632.2000.tb07062.x

DO - 10.1111/j.1749-6632.2000.tb07062.x

M3 - Article

C2 - 11193920

AN - SCOPUS:0034509617

SN - 0077-8923

VL - 922

SP - 349

EP - 351

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

ER -

Phase II study of intravenous DX-8951f in patients with advanced ovarian, tubal, or peritoneal cancer refractory to platinum, taxane, and topotecan

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this